Press Releases

Ventripoint Clarifies News Release of December 17, 2019

Toronto, Ontario, December 19, 2019 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT, OTCQB:VPTDF) wishes to clarify the news release of December 17, 2019. 
The Company is not in receivership and it has not made an assignment under the Bankruptcy and Insolvency Act.  The Company is organizing a private placement and expects to resume normal operations in the new year.

Ventripoint Diagnostics Provides Corporate Update

Toronto, Ontario, December 17, 2019 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT, OTCQB:VPTDF) announces that the Board of Directors of the Company had deemed the Company was no longer a going concern and elected to put the Company into receivership.  Subsequently, Dr. Don Segal, David Willis, Dr. Alan Rabinowitz have resigned as Directors of the Company.  Justin Leuschner has resigned as a Director and CEO of the Company. Ellen Briant has resigned as CFO. Desmond Hirson has resigned as the CTO and will be available to the Company as a consultant.  The Company has given notice to its employees and has stopped operations until new funds are secured...

A restructuring plan has been put together by Dr. George Adams, who will become the Executive-Chairman of the Company and will run the Company in the interim. Read more...

​Ventripoint Announces Appointment of Justin Leushner as CEO and Changes to the Board of Directors

Toronto, Ontario, November 4, 2019 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT, OTCQB:VPTDF) is pleased to announce it has appointed Justin Leushner as CEO of Ventripoint. Dr. George Adams has resigned as CEO and has been elected as Chairman of the Board of Directors of Ventripoint. Read More...

Ventripoint President Justin Leushner joined Steve Darling from Proactive’s New York studio to discuss his new role with the company and Ventripoint's exciting new developments 

​Ventripoint Diagnostics Announces U.S. FDA Clearance for VMS+ 3.0 Whole Heart Analysis System

Toronto, Ontario, October 17, 2019 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT, OTCQB:VPTDF) is pleased to announce that they have received U.S. Food and Drug Administration (FDA) clearance for the VMS+ 3.0 whole heart analysis system.
​Read More...

​St. Michael’s Hospital to Receive VMS+ 3.0 Whole-Heart
Analysis System

Toronto, Ontario, October 16, 2019 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT, OTCQB:VPTDF) is pleased to announce that St. Michael’s Hospital in Toronto will be receiving the VMS+ 3.0 complete heart analysis system for use in clinical evaluations of cardiac patients. Read More...

​Ventripoint Announces Closing of Non-Brokered Private Placement

Toronto, Ontario, October 3, 2019 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Corporation”, TSXV:VPT, OTCQB:VPTDF) announces the closing of a non-brokered private placement (the “Private Placement”). Read More...

Ventripoint Announces Extension of Private Placement
and Shares for Debt Transaction

 Toronto, Ontario, September 26, 2019 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Corporation”, TSXV:VPT, OTCQB:VPTDF) announces that, further to its news release of August 16, 2019, the TSX Venture Exchange (the “Exchange”) has granted an extension with respect to the duration of the Corporation’s previously-announced private placement (the “Private Placement”). Read More...

​Ventripoint Diagnostics Announces Justin Leushner as New President and Management Restructuring

Toronto, Ontario, September 19, 2019 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT, OTCQB:VPTDF) is pleased to announce that Justin Leushner has been appointed the President of Ventripoint. Read More...

​Children’s Hospital in Western Canada to Become First to Use Ventripoint Heart Analysis System for 3D Echocardiograms

Toronto, Ontario, August 21, 2019 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT, OTCQB:VPTDF) is pleased to announce that a children’s hospital in Western Canada will be the first hospital to use the VMS+ 3.0 software-only solution for the clinical assessment of pediatric cardiac patients using 3D ultrasound. Read More...

Ventripoint Announces $2,000,000 Non-Brokered Private Placement and Cross Trade

Toronto, Ontario, August 16, 2019 – Ventripoint Diagnostics Ltd. (“Ventripoint” or
the “Corporation”, TSXV:VPT, OTCQB:VPTDF) announces that it intends to
complete a non-brokered private placement (the “Private Placement”) of up to
13,333,333 units of the Corporation (“Units”) at CDN$0.15 per Unit for total gross
proceeds of up to CDN$2,000,000 (the “Offering”). Each Unit will be comprised of:
(i) one common share of the Corporation (“Common Share”); and (ii) one common
share purchase warrant (“Warrant”) with each Warrant exercisable for one
Common Share at an exercise price of CDN$0.175 per Common Share for a
period of 36 months after the issuance of the Warrant. Depending on market
conditions, the Corporation reserves the right to increase the maximum gross
proceeds under the Offering, subject to approval of the TSX Venture Exchange
(the “Exchange”). Read More...

Ventripoint Commends Mazankowski Alberta Heart Institute on their Feasibility Study Finding the VMS+ System Can Obviate the Need for Contrast Agents for LV Volumes and EF

Toronto, Ontario, August 06, 2019 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT, OTCQB:VPTDF) is pleased to announce that Dr. Windram and his group of researchers at the Mazankowski Alberta Heart Institute in Edmonton have completed a clinical study on the ability of the VMS+ whole-heart analysis system to analyze 2D echocardiograms of left-ventricle (LV) volumes and ejection fractions (LVEF) without the need for intravenous ultrasonographic enhancing agents. This feasibility study concluded: “The use of the Ventripoint knowledge-based-reconstruction technique revealed no significant differences in the measurement of left ventricular volumes or ejection fraction in comparison with contrast echocardiography measurements.” Read More...

Ventripoint Manufacturing Facility Passed Inspection and First Two VMS+ 3.0 Heart Analysis Machines Shipping to Western Canada

Toronto, Ontario, July 31, 2019 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”,
TSXV:VPT, OTCQB:VPTDF) is pleased to announce that its manufacturing facility for the VMS+ 3.0
whole heart analysis system received its initial inspection and passed on July 25th, 2019. The first two devices are being fabricated and are on schedule to ship this week to fulfill purchase orders at a Heart Institute and a Children’s Hospital in Western Canada (see Ventripoint News Releases from July 15th & 16th, 2019). Read More...

A Second Canadian Heart Institute to Receive Ventripoint
VMS+ 3.0 Whole-Heart Analysis System

Toronto, Ontario, July 23, 2019 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the
“Company”, TSXV:VPT, OTCQB:VPTDF) is pleased to announce that a second
Canadian Heart Institute has ordered a VMS+ 3.0 complete heart analysis system for
the assessment of adult cardiac patients. Read More...

A Canadian Heart Institute to Receive Ventripoint VMS+ 3.0
​Whole-Heart Analysis System

Toronto, Ontario, July 16, 2019 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the
“Company”, TSXV:VPT, OTCQB:VPTDF) is pleased to announce that a Canadian Heart
Institute has ordered a VMS+ 3.0 complete heart analysis system for the assessment of
cardiac patients.
Read More...

Canadian Children’s Hospital to Receive Ventripoint VMS+ 3.0 For Clinical Assessment of Pediatric Cardiac Patients

Toronto, Ontario, July 15, 2019 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the
“Company”, TSXV:VPT, OTCQB:VPTDF) is pleased to announce that a leading
Canadian Children’s Hospital will be the first pediatric hospital to receive the VMS+ 3.0
complete heart analysis system for the clinical assessment of pediatric cardiac patients. 
Read More...

Ventripoint Receives CE Mark for Clinical Use of VMS+ 3.0
​Whole-Heart Analysis System

Toronto, Ontario, July 2, 2019 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the
“Company”, TSXV:VPT, OTCQB:VPTDF) is pleased to announce that they have received
CE Mark for the VMS+ 3.0 system allowing it to be sold for clinical use throughout the
European Union and other CE Mark countries. The VMS+ system can be used for all four
chambers of the patient’s heart to obtain volumetric measurements and is a valuable tool
for clinicians when diagnosing patients with cardiac problems. Read More...

Ventripoint VMS+ 3.0 Whole-Heart Analysis System Receives License for Clinical Use from Health Canada

Toronto, Ontario, June 25, 2019 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the
“Company”, TSXV:VPT, OTCQB:VPTDF) is pleased to announce that they have received
a license from Health Canada to market the VMS+ 3.0 cardiac system for all patients
where the Left Ventricle (LV), Right Ventricle (RV), Left Atrium (LA), and Right Atrium
(RA) volumes and ejection fractions are warranted or desired. 
Read More...

Ventripoint to Exhibit VMS+ Technology at the American Society of Echocardiography Annual Scientific Sessions

Toronto, Ontario, June 21, 2019 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT, OTCQB:VPTDF) is pleased to announce that they are showcasing the VMS+ 3.0 cardiac system and VMS+ Software Solution at the American Society of Echocardiography’s 30th Annual Scientific Sessions in Portland, Oregon. Read More...

Ventripoint Completes Usability Study for VMS+ 3.0 with Positive Results

Toronto, Ontario, June 17, 2019 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT, OTCQB:VPTDF) is proud to announce that they have completed a usability study for the VMS+ 3.0 system with very positive results. Read More...

​Ventripoint to Manufacture VMS+ 3.0 In-House at Toronto Headquarters

Toronto, Ontario, June 10, 2019 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT, OTCQB:VPTDF) is pleased to announce that they will be setting up manufacturing operations at their Toronto headquarters for the new generation of VMS+ system. Manufacturing of the current VMS+ system was out-sourced to a contract manufacturer. Read More...

​Ventripoint Files Regulatory Submissions for Next-Generation VMS+ 3.0 System in Major Markets

Toronto, Ontario, June 5, 2019 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT, OTCQB:VPTDF) is pleased to announce that they have submitted for regulatory approvals in Canada, United States and Europe for their next-generation VMS+ 3.0 system. Read More...

​Ventripoint Achieves Major Milestone by Passing External Safety Testing for Next-Generation VMS+ 3.0

Toronto, Ontario, May 31, 2019 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT, OTCQB:VPTDF) is pleased to announce that they have achieved a major milestone by successfully passing the EMC/Safety Testing for the VMS+ 3.0, which is required for regulatory premarket approvals in Canada, United States and Europe. Read more...

Ventripoint Featured in Canadian Business Quarterly for Paving a New Path in Cardiology Care with its AI-Powered Technology

Toronto, Ontario, May 21, 2019 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT, OTCQB:VPTDF) is pleased to announce that they have been featured in the Canadian Business Quarterly publication for their revolutionary VMS+ device that makes diagnosing and monitoring heart diseases faster, less expensive and with equivalent accuracy to MRI.
Read More...

Ventripoint Signs an Authorized Sales Agent Agreement with Irudigi

​Toronto, Ontario, May 15, 2019 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT, OTCQB:VPTDF) is pleased to announce that they have signed an Authorized Sales Agent Agreement with Irudigi out of France. Read more...

Ventripoint to Exhibit VMS+ 3.0 at the Canadian Society of Echocardiography 21st Annual Symposium

Toronto, Ontario, April 1, 2019 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT, OTCQB:VPTDF) is pleased to announce that they are a proud sponsor of the 21st Annual Canadian Society of Echocardiography Annual Symposium and will be exhibiting the VMS+ 3.0 system. Read more...

Canada’s Largest Heart Health Centre Orders VMS+ Complete Heart Analysis System

Toronto, Ontario, March 25, 2019 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT, OTCQB:VPTDF) is pleased to announce that the University of Ottawa Heart Institute has ordered the VMS+ complete heart analysis system for the clinical assessment of cardiac patients. ​Canada’s Largest Heart Health Centre Orders VMS+ Complete Heart Analysis System​. Read More....

Ventripoint Provides Live Demonstrations of the VMS+3.0 System at American College of Cardiology 68th Annual Conference

Toronto, Ontario, March 19, 2019 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT, OTCQB:VPTDF) is pleased to announce that it successfully showcased the next-generation VMS+3.0 system at the American College of Cardiology’s 68th Annual Scientific Session & Expo. Read more...

Ventripoint Announces TSXV Approval of Extension of Warrants and Clarifies Warrants Subject to Extension

Toronto, Ontario – March 14, 2019 - Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Corporation”) (TSXV:VPT, OTCQB:VPTDF) has received the approval of the TSX Venture Exchange (“TSXV”) in respect of the previously-announced extension of warrants issued in connection with a private placement of the Corporation on March 23, 2017 (the “Private Placement Warrants”). The warrants issued in connection with a shares-for-debt transaction of the Corporation on March 21, 2017 (the “Shares-for-Debt Warrants”) will not be amended. 
Read more...

Ventripoint Announces Press Release Correction

Toronto, Ontario – March 6, 2019 - Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Corporation”) (TSXV:VPT) announces a correction to the press release dated March 6, 2019 entitled “Ventripoint Announces Extension of Warrants”. Read more...

Ventripoint Announces Extension of Warrants

Toronto, Ontario – March 6, 2019 - Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Corporation”), (TSXV:VPT, OTCQB:VPTDF) announces that it has applied to the TSX Venture Exchange (the “TSXV”) to extend the expiry dates of common share purchase warrants issued by the Corporation (the “Warrants”) in connection with a private placement on March 23, 2017 and a shares-for-debt transaction on March 21, 2017 (collectively, the “Originating Transactions”). Read more...

Ventripoint’s VMS System Approved for Sale and Clinical Use in China

Toronto, Ontario, March 4, 2019 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT, OTCQB:VPTDF) is pleased to announce that its Partner,  Ma’anshan YuTian Medical Technology Co. Ltd (“YuTian Technology”), has received CFDA approval and a Certificate of Production (CoP) from the FDA in the People’s Republic of China for the VMS (QAS-R in China) system to be clinically used to analyze the right ventricle (RV) of the heart.
Read more...

Ventripoint to Exhibit the VMS+ 3.0 System at American College of Cardiology Annual Conference and Grant of Options

Toronto, Ontario, February 27, 2019 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT, OTCQB:VPTDF) is pleased to announce that it will be exhibiting at the American College of Cardiology’s 68th Annual Scientific Session & Expo to showcase its next-generation VMS+ 3.0 system (http://2019.acccongress.com). Read more...

Ventripoint Diagnostics Reports Progress of the Next-Generation VMS+ 3.0 System and Remote Workstation

Toronto, February 5, 2019 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT, OTCQB:VPTDF) is pleased to announce the development stage of their next-generation VMS+ 3.0 product is nearing completion. Read more...

Ventripoint Announces Closing of Non-Brokered Debenture Unit Private Placement

Monday, January 28, 2019 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Corporation”, TSXV:VPT, OTCQB:VPTDF) is pleased to announce that it has closed its non-brokered private placement of debenture units of the Corporation (“Units”) for gross proceeds of $1,511,000 (the “Offering”). ​Read more...

Dr. George Adams, Ventripoint's CEO Joins Steve Darling from Proactive Investors to Discuss Recent Developments

Ventripoint Awarded MDSAP Certification, the Highest Quality Standards in the Medical Device Industry

Toronto, January 22, 2019 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT, OTCQB:VPTDF) is pleased to announce that it has successfully received the Medical Device Single Audit Program (MDSAP) certification, following an audit of its quality management system by our Notified Body/Registrar, an authorized third party auditing organization. Read more...

Ventripoint Announces Increase in Non-Brokered Debenture Unit
Private Placement

Toronto, Ontario, January 21, 2019 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Corporation”, TSXV:VPT) announces that as a result of positive investor response to its previously announced non-brokered unit private placement (the "Offering"), as disclosed in a news release dated January 9, 2019, the Corporation has increased the size of the Offering from $1,000,000 to $1,500,000.  Read more...

Ventripoint Announces $1,000,000 Non-Brokered Debenture Unit Private Placement

Toronto, Ontario, January 9, 2019 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Corporation”, TSXV:VPT) announces that it intends to complete a non-brokered private placement of up to CDN$1,000,000 (the “Offering”) of debenture units of the Corporation at CDN$1,000 per Unit (“Unit”). Read more...

St. Antonius Hospital in Nieuwegein/Utrecht, The Netherlands Has Studied 500 Sarcoidosis Patients Using the Ventripoint Heart-Analysis System

Toronto, January 7, 2019 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT, OTCQB:VPTDF) is pleased to announce that Dr. M.C. Post, MD, PhD Cardiologist and Dr. Marloes Huitema, MD, PhD candidate Cardiology at St. Antonius Hospital in Nieuwegein/Utrecht, the Netherlands, are using the VMS System to study patients with sarcoidosis, an inflammatory disease that affects multiple organs in the body, including the heart. Read more...

Ventripoint Performs Live Demonstrations of the Next-Generation VMS+ System at EuroEcho 2018

Toronto, Ontario, December 14, 2018 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT, OTCQB:VPTDF) is pleased to announce that it showcased the VMS+ 3.0 System at EuroEcho 2018 in Milan, Italy, one of the world’s largest cardiovascular imaging congress’ with 4,200 attendees.  Read more...

Ventripoint Announces CEO to Give Medical Keynote Presentation at Wall Street Conference in January and Engagement of Lyons Capital LLC

Toronto, Ontario – December 13, 2018 - Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”) (TSXV:VPT, OTCQB:VPTDF) announces that it has entered into a contract with Lyons Capital LLC. (“Lyons”) for a Platinum Sponsorship and a Medical Keynote presentation slot at the 2019 Wall Street Conference on January 16, 2019 at Mar-a-Lago, Florida,  and for introductions within the investment community to increase market exposure, Read More...

Ventripoint to Exhibit the Next-Generation VMS+ System
at EuroEcho in Milan, Italy

Toronto, Ontario, November 29, 2018 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT, OTCQB:VPTDF) is pleased to announce that it will be exhibiting at EuroEcho 2018, the annual congress of the European Association of Cardiovascular Imaging to showcase the next-generation VMS+ System. Read more...

Ventripoint Diagnostics Announces Extension of Warrants

Toronto, Ontario – November 28, 2018 - Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Corporation”) (TSXV:VPT) announces that it has applied to the TSX Venture Exchange (the “TSXV”) to amend the expiry date of common share purchase warrants issued by the Corporation in connection with a private placement of the Corporation (the “Originating Private Placement”) on December 16, 2016 (the “Warrants”). Read more...

HDZ NRW Heart and Diabetes Center in Germany has Begun Using VMS+ Software for Left Ventricular Volumetric Analysis

Toronto, November 20, 2018 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT, OTCQB:VPTDF) is pleased to announce that Dr. Kai Thorsten Laser, an internationally renowned pediatric cardiologist at the HDZ NRW Heart and Diabetes Center in Germany, has begun using VMS+ software for 3D Echo analysis of the left ventricle. Read more...

Ventripoint’s Product Offering is Now Extended to Include VMS+ Software for the Analysis of 3D Echo Studies

Toronto, Ontario, November 19, 2018 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT, OTCQB:VPTDF) is pleased to announce that the VMS+ Software approved for all 4 chambers of the heart can be used for the analysis of 3D echo images generated by any commercially available 3D echocardiography system. Read more...

Ventripoint Has Been Approved for Government Support to Aid in the Extension of VMS Technology to Provide 4D Data

Toronto, Ontario, November 14, 2018 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT) is pleased to announce that it has entered into a Contribution Agreement with the Government of Canada.  The National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) will provide both advisory support and conditional funding to share the costs of a project designed to accelerate the further development of the Ventripoint VMS+ system’s next-generation products. Read more...

St. Michael’s Hospital, a Leading Cardiac Centre in Canada, Orders the Ventripoint Artificial Intelligence VMS+ Complete Heart Analysis System

Toronto, Ontario, November 12, 2018 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT) is pleased to announce that St. Michael’s Hospital in Toronto,  Canada, has ordered the AI based VMS+ complete heart analysis system for use in clinical evaluations of cardiac patients. Read more...

The University of Chicago Medical Center Cardiac Department Evaluates the VMS+ Complete Heart Analysis System

Toronto, Ontario, November 5, 2018 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT, OTCQB:VPTDF) is pleased to announce that the University of Chicago Medical Center in Chicago, Illinois will be receiving the VMS+ complete heart analysis system.
Read more...

Ventripoint is Now Listed on the OTCQB in the United States

Toronto, Ontario, October 24, 2018 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV: VPT, OTCQB: VPTDF) is pleased to announce that, as of October 23, 2018, the Company’s common shares are now trading on the OTCQB Venture Market for early stage and developing U.S. and international companies, under the stock symbol ‘VPTDF’.   Read more...

Ventripoint Diagnostics Announces New Marketing Manager and Provides Corporate Update on Sales

Toronto, Ontario, October 17, 2018 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT) is pleased to announce that Jessica Naman has joined Ventripoint as Marketing Manager and will be responsible for conceiving and executing marketing strategies and tactics for the growth of the current VMS+ system along with the rollout and expansion of the next generation product line. Read more...

Ventripoint Closes Final Tranche of Non-Brokered Private Placement

Toronto, Ontario, September 14, 2018 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT) announces that, further to its news release of September 4, 2018, it has closed the second and final tranche (the “Final Tranche”) of its non-brokered private placement announced on August 15, 2018 (the “Private Placement”). Read more...

Ventripoint Closes First Tranche of Non-Brokered Private Placement

​Toronto, Ontario, September 5, 2018 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT) announces that it has closed the first tranche of its non-brokered private placement announced on August 15, 2018 (the “Private Placement”). Read more...

Ventripoint Announces $1,000,000 Non-Brokered Private Placement 

​Toronto, Ontario, August 15, 2018 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT) announces that it intends to complete a non-brokered private placement (the “Private Placement”) of up to 4,761,905 units (“Units”) at $0.21 per Unit for total gross proceeds of up to $1,000,000 (the “Offering”). Read more...

Ventripoint Provides Corporate Update on Development of Artificial Intelligence Engine to Automate Heart Analysis

​Toronto, Ontario, August 13, 2018 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT) is pleased to present an update on its progress to provide better tools for cardiac analysis to cardiologists to improve diagnosis and treatment of heart disease. Read more...

Ventripoint Provides Corporate Update on Development of
Next-Generation Products

​Toronto, Ontario, August 8, 2018 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT) is pleased to present an update on its progress to provide better tools for cardiac analysis to cardiologists to improve diagnosis and treatment of heart disease. Read more...

Ventripoint Provides Corporate Update on Sales and Marketing

​Toronto, Ontario, August 1, 2018 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT) is pleased to present an update on its progress to provide better tools for cardiac analysis to cardiologists to improve diagnosis and treatment of heart disease. Read more...

Mazankowski Alberta Heart Institute Starts Study ​Comparing Ventripoint Heart Analysis to Contrast Enhanced 2D Echocardiography

Toronto, Ontario, July 17, 2018 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT) is pleased to announce that the Mazankowski Alberta Heart Institute in Edmonton, Alberta has begun a study to evaluate the ability of the Ventripoint VMS+ heart analysis system to analyze poor quality images, where contrast enhanced 2D echocardiography would normally be performed to get better images.  Read more... 

MD Anderson Cancer Center is the First Hospital in USA to Order the VMS+ Complete Heart Analysis System

​Toronto, Ontario, June 6, 2018 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT) is pleased to announce that MD Anderson Cancer Center in Houston, Texas has ordered the VMS+ complete heart analysis system for use in clinical evaluations of cancer patients.  Read more...

Ventripoint adds Experienced Cardiac Sonographer to the Installation and Training Team

Toronto, Ontario, May 23, 2018 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT) is pleased to announce the appointment of Jim Graba, BSc, RDCS, FASE  as Application Specialist and Chief Trainer.  Jim will take the clinical lead in the deployment and training of customers.  In addition, he will provide product strategy and direction for the development team. Read more...

Ventripoint Receives Market Clearance from US-FDA for Complete Heart Analysis System using 2D Ultrasound 

Toronto, Ontario – May 15, 2018 - Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”) (TSXV:VPT) announces that it has received market clearance from the US Food and Drug Administration (“FDA”) to sell its VMS+™ machine with the 4-chamber heart analysis system in the United States. Read more....

​Ventripoint Attends the Canadian Society of Echocardiography Conference in Toronto

​Toronto, Ontario, April 23, 2018 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT) is pleased to announce that it exhibited at the 20th annual Canadian Society of Echocardiography conference which was recently held in Toronto.  Read more...

Ventripoint to Issue Shares for Service to CEO and Consultants

Toronto, Canada – March 29, 2018 - Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”) (TSXV:VPT) is pleased to announce that it has agreed to issue to Dr. George Adams, CEO of Ventripoint, 375,000 common shares of the Company in payment of  outstanding back pay of $120,000, subject to the approval of the TSX Venture Exchange (TSXV).  Read more...

​Ventripoint and Ryerson University Have Been Approved for Government Funding to Advance Artificial Intelligence in Medical Imaging

​Toronto, Ontario, March 26, 2018 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT) is pleased to announce its participation in a Natural Sciences and Engineering Research Council (NSERC) Engage grant for the development of automatic detection of all four chambers of the heart in echocardiographic views using artificial intelligence (AI), which will reduce time spent on analysis and training costs, and improve accuracy and comparability. Read more...

Ventripoint Appoints Dr. Samuel Schwartz Chair of Business Advisory Committee

​Toronto, Ontario, March 14, 2018 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT) is pleased to announce that it has created a Business Advisory Committee (BAC) and has appointed Dr. Samuel Schwartz as the inaugural Chairman.  The BAC will provide senior management and the Board of Directors with strategic advice on matters including, but not limited to, financing alternatives and opportunities, market opportunities, human resource insights, and new technology perspectives, in addition to carrying out special assignments. Read more...

Ventripoint Named to 2018 TSX Venture 50 Group of Top Performing Companies

Picture
​​Toronto, Canada – February 22, 2018 - Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”) (TSXV:VPT) is pleased to announce that it has been named to the 2018 TSX Venture 50, a ranking of the top performers on the TSX Venture Exchange over the last year.
Read more...

First Ventripoint Whole Heart System Operational at University of Alberta Mazankowski Heart Institute

Toronto, Canada – February 21, 2018 - Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”) (TSXV:VPT) is pleased to announce the installation of the VMS+ whole heart analysis system at the University of Alberta Mazankowski Alberta Heart Institute under the supervision of Dr. Jonathan Windram, Staff Cardiologist, Northern Alberta Adult Congenital Heart Program and Associate Clinical Professor of Medicine, Division of Cardiology, Department of Medicine, University of Alberta Mazankowski Alberta Heart Institute. Read more...

Ventripoint Adds Hospital Networking Expert to Implementation Team

Toronto, Ontario, February 7, 2018 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT) is pleased to announce that Dr. Andriy Shmatukha has joined the Ventripoint team as software developer to advance the Ventripoint products and technology. Read more...

Ventripoint Applies to US FDA for Market Clearance for the VMS+ Whole-Heart Analysis System

​Toronto, Ontario, January 17, 2018 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT) is pleased to announce that it has submitted a traditional 510(k) application to the FDA’s Center for Devices and Radiological Health (CDRH) to request clearance for sale of the VMS+ whole-heart analysis system. Read more...

Ventripoint Appoints Head of Sales for North America

​Toronto, Canada – January 10, 2018 - Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”) (TSXV:VPT) is pleased to announce the appointment of David McPhedran as Director  of Sales for North America, effective immediately. Read more...

Ventripoint Receives CE Mark for VMS+ Whole Heart Analysis System

​Toronto, Ontario, January 8, 2018 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT) is pleased to announce that it has received the European CE Mark for the VMS+ Whole Heart Analysis System, which allows the Company to begin selling the VMS+ throughout the European Union. Read more...

 Ventripoint Applies for CE Mark for VMS+ Device and Complete Heart Analysis System

​Toronto, Ontario, December 20, 2017 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT) is pleased to announce that it has applied to its Notified Body in Europe to add the new product, VMS+, to its CE Mark and to its certified quality system. Read more...

Ventripoint Provides Corporate Update

Toronto, Ontario, December 19, 2017 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT) is pleased to announce that it has hired a Manager of Regulatory Affairs and Quality Assurance, promoted to President the VP, Development and Operations, completed the ISO60601 safety testing for the VMS+ device and moved its Development and Manufacturing Centre, as well as its Corporate Offices. Read more...

Ventripoint Exhibits at Major Heart Imaging Conference in Europe

​Toronto, Ontario, December 6, 2017 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT) is pleased to announce that it is exhibiting at the EuroEcho- Imaging 2017 Conference in Lisbon, Portugal, December 6 – 8, 2017.  The Conference is the world’s largest cardiovascular imaging congress.  Read more...

Ventripoint Invents a New Way to Track Ultrasound Probes That Will Speed Up Exams

​Toronto, Ontario, November 27, 2017 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT) is pleased to announce that it has filed a patent to claim the invention of a small, low-cost device that attaches or is encased in any hand-held probe or ultrasound transducer.  The invention also includes a method to use the device to track the probe’s position in 3-dimensional space, as well as its orientation. Read more...

Ventripoint Establishes Partnership with the SEED Group from Dubai to Begin Deploying VMS-PLUS Heart Analysis Systems in the Middle East

Toronto, Ontario, November 15, 2017 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT) is pleased to announce that it has signed a memorandum of understanding establishing a partnership with the SEED Group, a group of diversified companies owned and chaired by The Private Office of Sheikh Saeed Bin Ahmed Al Maktoum of Dubai, United Arab Emirates. Read more...​

Ventripoint Provides Corporate Update

Toronto, Ontario, September 20, 2017 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT) is pleased to provide a corporate update on its marketing and development plans. Read more...
​

Ventripoint Reports on Use of VMS Heart Analysis System to Reliably Measure Remodelling of the Right Ventricle

Toronto, Ontario, August 21, 2017 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT) announces that the cardiology group at Royal Free Hospital in London, UK has published a study entitled “Two-dimensional knowledge-based volumetric reconstruction of the right ventricle documents short-term improvement in pulmonary hypertension” in Echocardiography, volume 34, pages 817–824. "Read more.."

Ventripoint Announces Results of Annual Shareholders’ Meeting and Grant of Options and DSUs ​

Toronto, Ontario, August 16, 2017 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Corporation”, TSXV:VPT) announces that at its Annual General Meeting on August 14, 2017 the shareholders re-elected Dr. George Adams, Mr. Danny Dalla-Longa, Dr. Alan Rabinowitz, Dr. Don Segal and Mr. David Willis as Directors of the Corporation. "Read more..."

A Third Highly Successful Ultrasound Executive Joins Ventripoint

​Toronto, Canada – July 20, 2017 - Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”) (TSXV:VPT) is announcing the appointment of Desmond Hirson as Vice-President, Development and Operations. "Read more..."

Highly Successful Global Industry (Ultrasound) Sales & Marketing Executives Hired by Ventripoint

Toronto, Canada – June 21, 2017 - Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”) (TSXV:VPT) is announcing the appointment of Brian Leck as Vice-President of Direct Worldwide Sales and Mehran Mehrtash as Vice President, Worldwide Distributor Sales, both effective July 1, 2017. "Read more..."

Ventripoint Provides Corporate Update on Sales Initiatives​

Toronto, Canada – June 8, 2017 - Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”) (TSXV:VPT) is pleased to provide a corporate update on its business activities. "Read more..."

​Ventripoint Diagnostics Ltd is Featured on ​CEO Clips Airing on BNN

Toronto, Ontario - March 30, 2017 - Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Corporation”) (TSXV:VPT) is please to announce the Corporation is being featured this week on CEO Clips airing on BNN.  CEO Clips, profiles some of the most innovative publicly-traded companies in North America and will feature a 15 to 30 second clip about Ventripoint on BNN beginning today. The clip can also be viewed online via this link: http://www.b-tv.com/ventripoint-diagnostics-commercial/
"Read more..."

Ventripoint Announces Conversion of all Outstanding
Debentures and Exercise of Warrants

​Toronto, Ontario - March 29, 2017 - Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Corporation”) (TSXV:VPT) announces that it is now “debt free” due to the conversion of all outstanding debentures previously issued by the Corporation. "Read more..."

Ventripoint Announces Closing of Private Placement

Toronto, Ontario - March 24, 2017 - Ventripoint Diagnostics Ltd. (“Ventripoint” or the ”Corporation”) (TSXV:VPT) is pleased to announce that it has closed its previously-announced non-brokered private placement (the “Private Placement”) of 10,496,938 units (“Units”) at $0.32 per Unit for total gross proceeds of $3,359,020. Existing shareholders subscribed for $1.9M and new shareholders subscribed for $1.4M of the Private Placement. "Read more..."

Ventripoint Announces Closing of Shares for Debt and New Closing Date for Private Placement

Toronto, Ontario - March 22, 2017 - Ventripoint Diagnostics Ltd. (“Ventripoint” or the ”Corporation”) (TSXV:VPT) is pleased to announce that it has completed its previously-announced, shares-for-debt transaction (the “Shares for Debt”) with holders of debentures previously issued by the Corporation (the “Debentures”). The Corporation issued to the holders of Debentures a total of 1,575,000 units of the Corporation (“Units”) as payment of $504,000, being the aggregate of all amounts due under such Debentures. "Read more..."

Ventripoint Announces Increase in Size of Private Placement, Shares for Debt and Closing of Acceptance of Orders

Toronto, Ontario, March 15, 2017 – Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Corporation") (TSXV:VPT) is pleased to announce that the Corporation is increasing the maximum gross proceeds of its previously-announced non-brokered private placement (the "Private Placement") from $2,000,000 to $3,200,000 and will now issue up to 10,000,000 units ("Units") at $0.32 per Unit.  "Read more..."

Ventripoint Announces $2,000,000 Non-Brokered Private Placement

Toronto, Ontario, March 9, 2017 – Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Corporation") (TSXV:VPT) announces that it intends to complete a non-brokered private placement (the "Private Placement") of up to 6,250,,000 units "Units") at $0.32 per Unit for total gross proceeds of up to $2,000,000 (the "Offering"). "Read more..."

Approval for World's First Complete Heart Analysis System for 2D Ultrasound Exams Received by Ventripoint

 Toronto, Ontario – March 2, 2017 - Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”) (TSXV:VPT) announces that it has received a license from Health Canada for the new VMS-PLUS machine and the 4-chamber (4C) heart analysis system.  This is an expansion of the VMS heart analysis product to include right atrium (RA), left atrium (LA) and left ventricle (LV) chambers of the heart.  The VMS was already licensed in Canada for use for the right ventricle (RV).   This expansion allows for the determination of volume and function for all four chambers of the heart using conventional 2D ultrasound, which could only be provided by MRI until now. "Read more..."

Ventripoint Announces Filing of Application for Complete Heart Analysis System with Health Canada

​Toronto, Ontario – January 17, 2017 - Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”) (TSXV:VPT) announces that it has filed an application with Health Canada for approval of the expansion of the VMS™ heart analysis product to include right atrium (RA), left atrium (LA) and left ventricle (LV) chambers of the heart. The VMS is already licensed in Canada for use for the right ventricle (RV). "Read more..."

​Ventripint Announces the Engagement of FronTier Consulting

Toronto, Ontario – January 6, 2017 - Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”) (TSXV:VPT) announces that it has engaged the services of FronTier Consulting Ltd. (part of the FronTier Merchant Capital Group) ("FronTier") to provide the Company with investor relations services in compliance with regulatory guidelines to increase market exposure. "Read more..."

Ventripoint Receives First Order for VMS-PLUS Components
​from China

Toronto, Ontario – October 31, 2016 - Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”) (TSXV: VPT) announces it has received $240,534 from Ma’anshan YuTian Medical Technology Co. Ltd to purchase the first batch of components to begin the manufacturing process of the VMS-PLUS heart analysis units in China. "Read more..."

Ventripoint Announces Establishment of a Joint Venture in China

Toronto, Ontario – September 23, 2016 - Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”) (TSXV: VPT) announces an update on its strategy to develop, manufacture and distribute a family of Ventripoint’s knowledge-based reconstruction (“KBR”) products in the People’s Republic of China. "Read more..."

Ventripoint's Canadian Development and Manufacturing Centre Achieves ISO 13485 Registration

Toronto, Canada – June 24, 2016 - Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”) (TSXV:VPT) announces that it has successfully achieved ISO 13485 registration for the manufacturing and development centre in Toronto, Canada. This is a positive assessment of the Company’s quality management system and is a milestone in Ventripoint’s history, as it now allows the manufacture and design of VMS™ devices in Canada. "Read more..."

Ventripoint Announces TSXV Exchange Approval for Amendment of Warrants

​Toronto, Ontario – June 17, 2016 - Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Corporation”) (TSXV:VPT) has received approval from the TSX Venture Exchange (the “TSXV”) for the previously announced amendment of the terms of certain common share purchase warrants (the “Warrants”) issued by the Corporation in connection with private placements of the Corporation on August 21, 2013, October 22, 2013, June 20, 2014, December 31, 2014, June 4, 2015, and September 29, 2015. "Read more..."

Ventripoint Announces Change to the Board of Directors and Opening of Manufacturing Facility in Canada

​Seattle, Washington – February 15, 2016 - Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”) (TSXV:VPT) is pleased to announce that Dr. Don Segal has joined the Board of Directors of the Company replacing Mr. Treuman Katz, who has stepped down after 8 years as a Director of the Company. "Read more..."

Ventripoint Announces Licensing of Additional Heart Analysis Technology from the University of Washington

Seattle, Washington – January 21, 2016 - Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”) (TSXV:VPT) is pleased to announce that is has licensed the knowledge-based reconstruction (KBR) technology for the left atrium and right atrium of the heart. "Read more..."

​Ventripoint Announces Reverse Split

Seattle, Washington – December 07, 2015 - Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Corporation”) (TSXV:VPT) is pleased to announce that, effective today, the Corporation has consolidated its issued and outstanding common shares (the "Shares") on the basis of one (1) post-consolidated common Share for every ten (10) pre-consolidated Shares (the "Reverse Split"). ​"Read more..."

Ventripoint Receives Marketing Clearance from the FDA to Expand the Use of the VMS Heart Analysis System 

Seattle, Washington, May 25, 2015 – Ventripoint Diagnostics Ltd. ("Ventripoint") (TSXV:VPT) is pleased to announce that it has received Marketing Clearance from the U.S. Food & Drug Administration (“FDA”) for the expanded Indications for Use of its VMS™ product which states; “The VMS system is indicated for use where RV (right ventricle) volumes and ejection fractions are warranted or desired”. "Read more..."

Ventripoint Announces Response to Interactive Review for
Recent 501(k) Submission to FDA

Seattle, Washington, April 8, 2015 – Ventripoint Diagnostics Ltd. ("Ventripoint") (TSXV:VPT) is pleased to announce that it has completed the first round of review concerning the most recent 510(k) submission to the U.S. Food & Drug Administration ("FDA").  "Read more..."

Ventripoint Announces Acceptance Notification from US-FDA of Recent 510(k) Submission

Seattle, Washington, March 27, 2015 – Ventripoint Diagnostics Ltd. ("Ventripoint" or the “Company”) (TSXV:VPT) is pleased to announce that it has received Acceptance Review Notification concerning the Company’s recent 510(k) submission. "Read more..."

Ventripoint Applies to U.S. FDA to Expand Use of the VMS Heart Analysis System to all Types of Heart Disease

Seattle, Washington, March 16, 2015 – Ventripoint Diagnostics Ltd. ("Ventripoint") (TSXV:VPT) is pleased to announce that it has recently filed an additional submission for 510(k) clearance to the U.S. Food & Drug Administration (FDA). "Read more..."

First Patients Examined with Ventripoint’s Heart Analysis System in China at Shandong Provincial Hospital

Seattle, Washington, December 18, 2014 – Ventripoint Diagnostics Ltd. ("Ventripoint")
(TSXV:VPT) is pleased to announce that it has installed its VMS heart analysis system at the Shandong Provincial Hospital (SPH) in Jinan, China and has examined a number of patients. The SPH does 300 cardiac ultrasound exams a day and has nine other hospitals in its group. "Read more..."

Ventripoint Provides Corporate Update

Seattle, Washington, November 5, 2014 – Ventripoint Diagnostics Ltd. ("Ventripoint")
(TSXV:VPT) is pleased to provide this corporate update.
  • Major clinical paper published demonstrating excellent results for VMSTM in a number of clinically challenging heart conditions, including Hypoplastic Left Heart Syndrome
  • New sales in Europe, Canada and the USA and marketing success in USA
  • First VMS sent to China to be installed in major hospital
  • Re-admission clinical study started with 17 heart-failure patients enrolled
"Read more..."

German Heart Group Verifies Accuracy of Ventripoint’s VMS™ Heart Analysis Technology for Cardiac MRI and 3D Echocardiography Imaging

Seattle, Washington, July 7, 2014 – Ventripoint Diagnostics Ltd. ("Ventripoint") (TSXV:VPT) announces that a group led by Dr. Kai Laser at the Center for Congenital Heart Defects, Bad Oeynhausen, Germany, has published the results of a clinical study that demonstrates the robust application of the VMS heart analysis technology beyond 2D ultrasound imaging in a wide range of cardiac conditions. "Read more..."
For further information please contact:
George Adams, Executive-Chairman
Phone: (519) 803-6937
Email: gadams@ventripoint.com





























































​
















​

















​
​




























​


























​













​




























​​
​​

































​















​​


​
​
Website Design